High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 119, Issue 31, Pages -
Publisher
Proceedings of the National Academy of Sciences
Online
2022-07-27
DOI
10.1073/pnas.2205042119
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunological predictors of dimethyl fumarate‐induced lymphopenia
- (2022) Martin Diebold et al. ANNALS OF NEUROLOGY
- Mass Cytometry of CSF Identifies an MS-Associated B-cell Population
- (2021) David Johansson et al. Neurology-Neuroimmunology & Neuroinflammation
- Update on treatment in multiple sclerosis
- (2021) Ilaria Callegari et al. PRESSE MEDICALE
- Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
- (2020) Ludwig Kappos et al. JAMA Neurology
- Induction of brain‐infiltrating T‐bet‐expressing B cells in multiple sclerosis
- (2019) Jamie Langelaar et al. ANNALS OF NEUROLOGY
- GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis
- (2019) Edoardo Galli et al. NATURE MEDICINE
- Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
- (2019) Karl E. Carlström et al. Nature Communications
- Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
- (2019) SCIENCE
- Dimethyl Fumarate: A Review in Relapsing-Remitting MS
- (2019) Hannah A. Blair DRUGS
- Pathogenic T cell cytokines in multiple sclerosis
- (2019) Catriona A. Wagner et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients
- (2019) Jan W. Traub et al. Journal of Neuroinflammation
- IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis
- (2019) Christina Lückel et al. Nature Communications
- Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis
- (2019) Rikke Holm Hansen et al. Multiple Sclerosis and Related Disorders
- T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention
- (2018) Jamie van Langelaar et al. BRAIN
- Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis
- (2018) Martin Diebold et al. JOURNAL OF AUTOIMMUNITY
- Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients
- (2018) Ester Canto et al. Journal of Neuroinflammation
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- Multiple Sclerosis
- (2018) Daniel S. Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity
- (2018) Michael D. Kornberg et al. SCIENCE
- Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients
- (2018) G. Montes Diaz et al. Scientific Reports
- Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis
- (2018) Rikke Holm Hansen et al. Multiple Sclerosis Journal
- Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies
- (2018) Gwendoline Montes Diaz et al. AUTOIMMUNITY REVIEWS
- Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
- (2018) Stefan Gingele et al. Cells
- Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients
- (2017) Qi Wu et al. JOURNAL OF IMMUNOLOGY
- Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
- (2017) Silvia Medina et al. Multiple Sclerosis Journal
- Sensitive detection of rare disease-associated cell subsets via representation learning
- (2017) Eirini Arvaniti et al. Nature Communications
- Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
- (2017) Silvia Medina et al. Multiple Sclerosis Journal
- Dimethyl fumarate alters B-cell memory and cytokine production in MS patients
- (2017) Matthew D. Smith et al. Annals of Clinical and Translational Neurology
- Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis
- (2016) Rui Li et al. JOURNAL OF IMMUNOLOGY
- Immunological treatment of multiple sclerosis
- (2016) Martin Diebold et al. SEMINARS IN HEMATOLOGY
- FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data
- (2015) Sofie Van Gassen et al. CYTOMETRY PART A
- B Cells and Autoantibodies in Multiple Sclerosis
- (2015) Anne-Katrin Pröbstel et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- STAT4 controls GM-CSF production by both Th1 and Th17 cells during EAE
- (2015) Ian L. McWilliams et al. Journal of Neuroinflammation
- Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
- (2015) Erin E Longbrake et al. Multiple Sclerosis Journal
- Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
- (2015) Erin E Longbrake et al. Multiple Sclerosis Journal
- Effects of dimethyl fumarate on lymphocyte subsets
- (2015) Regina Berkovich et al. Multiple Sclerosis and Related Disorders
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis
- (2012) Lars Börnsen et al. PLoS One
- Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
- (2011) S. C. Bendall et al. SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started